Sign In
Buy NOEJF
Norma Group Se Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | - |
| EPS actual | $0.0347 |
| Revenue estimate | 200M |
| Revenue actual | 241.01M |
| Revenue Surprise | 20.51% |
| Release date | Mar 31, 2026 |
| EPS estimate | -$0.83 |
| EPS actual | -$0.223 |
| EPS Surprise | 73.24% |
| Revenue estimate | 1.334B |
| Revenue actual | 223.039M |
| Revenue Surprise | -83.28% |
| Release date | Nov 04, 2025 |
| EPS estimate | -$1.21 |
| EPS actual | -$2.19 |
| EPS Surprise | -81.55% |
| Revenue estimate | 264.212M |
| Revenue actual | 232.341M |
| Revenue Surprise | -12.06% |
| Release date | Aug 12, 2025 |
| EPS estimate | $0.401 |
| EPS actual | $0.381 |
| EPS Surprise | -4.97% |
| Revenue estimate | 341.647M |
| Revenue actual | 341.905M |
| Revenue Surprise | 0.0757% |
Last 4 Quarters for Norma Group Se
Below you can see how NOEJF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 12, 2025 |
| Price on release | $19.25 |
| EPS estimate | $0.401 |
| EPS actual | $0.381 |
| EPS surprise | -4.97% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $20.15 |
| Aug 07, 2025 | $20.15 |
| Aug 08, 2025 | $19.25 |
| Aug 11, 2025 | $19.25 |
| Aug 12, 2025 | $19.25 |
| Aug 13, 2025 | $19.25 |
| Aug 14, 2025 | $19.25 |
| Aug 15, 2025 | $19.25 |
| Aug 18, 2025 | $19.25 |
| 4 days before | -4.47% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | -4.47% |
| Release date | Nov 04, 2025 |
| Price on release | $20.25 |
| EPS estimate | -$1.21 |
| EPS actual | -$2.19 |
| EPS surprise | -81.55% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $20.25 |
| Oct 30, 2025 | $20.25 |
| Oct 31, 2025 | $19.25 |
| Nov 03, 2025 | $20.25 |
| Nov 04, 2025 | $20.25 |
| Nov 05, 2025 | $20.25 |
| Nov 06, 2025 | $20.25 |
| Nov 07, 2025 | $19.25 |
| Nov 10, 2025 | $20.25 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Mar 31, 2026 |
| Price on release | $16.90 |
| EPS estimate | -$0.83 |
| EPS actual | -$0.223 |
| EPS surprise | 73.24% |
| Date | Price |
|---|---|
| Mar 25, 2026 | $16.90 |
| Mar 26, 2026 | $16.90 |
| Mar 27, 2026 | $19.25 |
| Mar 30, 2026 | $16.90 |
| Mar 31, 2026 | $16.90 |
| Apr 01, 2026 | $16.90 |
| Apr 02, 2026 | $16.90 |
| Apr 06, 2026 | $16.90 |
| Apr 07, 2026 | $16.90 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | May 05, 2026 |
| Price on release | $16.90 |
| EPS estimate | - |
| EPS actual | $0.0347 |
| Date | Price |
|---|---|
| Apr 29, 2026 | $16.90 |
| Apr 30, 2026 | $16.90 |
| May 01, 2026 | $16.90 |
| May 04, 2026 | $16.90 |
| May 05, 2026 | $16.90 |
| May 06, 2026 | $19.25 |
| May 08, 2026 | $19.25 |
| May 11, 2026 | $19.25 |
| May 12, 2026 | $19.25 |
| 4 days before | 0% |
| 4 days after | 13.91% |
| On release day | 13.91% |
| Change in period | 13.91% |
Norma Group Se Earnings Call Transcript Summary of Q1 2026
NORMA Group delivered an encouraging Q1 2026 with a clear improvement in profitability and decisive progress on its NewNORMA transformation. Key financials: net sales €208.6m (‑5.7% YoY, impacted by FX headwinds), adjusted EBIT €6.3m (3.0% margin, +3.1pp YoY), and net operating cash flow negative €19.7m largely due to one‑off effects from the water management divestment. Management reports organic growth in Industrial Applications (+4.9% YoY) while Mobility & New Energy was softer. The transformation program (restructuring, footprint optimization, sales push, disciplined SG&A) is delivering early benefits (Q1 contribution ~€3.8m) and headcount/severance measures are underway. The water management sale is expected to generate ~€650m net proceeds in 2026; ~€290m of debt repayment has been executed, leaving the company effectively net‑debt free in Q1 and on track to return €260m to shareholders (€53m already returned via buyback). Guidance confirmed for FY26: net sales +0% to +2%, adjusted EBIT margin ~2%–4%, and net operating cash flow ~€10m–€20m. Management will provide a broader 2028 strategy update in H2 2026.
